CTLA4 and neoplasm: Mice treated with neoAg SLP vax in combination with anti-CTLA-4 or anti-PD-1 displayed enhanced tumor control compared to control vax + anti-PD-1 or control vax + anti-CTLA-4 (Figure S11A).